-
1.发明申请IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 审中-公开作为用于治疗细胞聚集的蛋白激活受体4（PAR4）抑制剂的咪唑唑二酮衍生物
公开(公告)号：WO2013163244A1
公开(公告)日：2013-10-31
申请号：PCT/US2013/037892
申请日：2013-04-24
发明人： LAWRENCE, Michael, R. , MILLER, Michael, M. , SEIFFERT, Dietmar, Alfred , POSY, Shoshana, L. , WONG, Pancras, C. , BANVILLE, Jacques , RUEDIGER, Edward, H. , DEON, Daniel, H. , MARTEL, Alain , TREMBLAY, Francois , GUY, Julia , LAVALLEE, Jean-Francois , GAGNON, Marc
IPC分类号： C07D519/00 , A61K31/433 , A61K31/4439 , C07D513/04 , A61P7/02
CPC分类号： C07D513/04 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00
摘要： The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, R x , R 1 , R 2 , R 3 , X 1 , X 2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
摘要翻译： 本发明提供式（I）的咪唑并噻二唑化合物，其中A，B，D，Rx，R1，R2，R3，X1，X2和s如本文所定义，或其立体异构体，互变异构体，药学上可接受的盐或溶剂化物形式， 其中所有变量如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作药物。
-
2.发明申请
公开(公告)号：WO2019036023A1
公开(公告)日：2019-02-21
申请号：PCT/US2018/000310
申请日：2018-08-16
IPC分类号： C07D473/18 , A61K31/522 , A61P37/04
摘要： Compounds having a structure according to formula (I) where R 1 , R 2 , and R 3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
-
公开(公告)号：WO2016138199A1
公开(公告)日：2016-09-01
申请号：PCT/US2016/019453
申请日：2016-02-25
IPC分类号： C07D513/04 , A61K31/433 , A61P7/02
CPC分类号： A61K31/426 , A61K31/495 , C07D513/04
摘要： The present invention provides benzothiazole compounds or benzothiophene compounds of Formula I having the structure: wherein X 1 , X 2 , X 3 , X 4 , X 5 , Y, WR 2 ,R 3 , R 4 , R 5 , R 6 , R 7 and AA and other moieties are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
摘要翻译： 本发明提供具有以下结构的式I的苯并噻唑化合物或苯并噻吩化合物：其中X1，X2，X3，X4，X5，Y，WR2，R3，R4，R5，R6，R7和AA等部分如本文所定义， 或立体异构体，互变异构体，药学上可接受的盐，前药酯或溶剂化物形式。 这些化合物是血小板聚集的抑制剂，因此可以用作治疗或预防血栓栓塞障碍的药物。
-
公开(公告)号：WO2022241172A1
公开(公告)日：2022-11-17
申请号：PCT/US2022/029105
申请日：2022-05-13
发明人： SPERGEL, Steven, H. , MOSLIN, Ryan, M. , MERTZMAN, Michael, Edward , POSY, Shoshana, L. , LAKKARAJU, Sirish, Kaushik , TINO, Joseph, A. , XIAO, Zili , LIU, Chunjian , LIN, James
IPC分类号： C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D417/12 , C07D417/14 , A61P29/00 , A61P37/00 , A61K31/501
摘要： There are disclosed compounds of the following formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
-
5.发明申请
公开(公告)号：WO2019035970A1
公开(公告)日：2019-02-21
申请号：PCT/US2018/000245
申请日：2018-08-16
IPC分类号： C07D473/18 , A61K31/522 , A61P37/04
摘要： Compounds having a structure according to formula (I) or (II), where R 1 , R 2 , and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
-
6.发明申请
公开(公告)号：WO2019035969A1
公开(公告)日：2019-02-21
申请号：PCT/US2018/000244
申请日：2018-08-16
发明人： YOUNG, Ian, S. , GANGWAR, Sanjeev , POSY, Shoshana, L. , POUDEL, Yam, B. , SIVAPRAKASAM, Prasanna
IPC分类号： C07D473/04 , A61K31/522 , A61P35/00 , A61P31/12
摘要： Compounds having a structure according to formula (I), (II), or (III) where R 1 , R 2 , R 3 , R 5 X 1 , X 2 , and X 3 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
-
7.发明申请
公开(公告)号：WO2019035968A1
公开(公告)日：2019-02-21
申请号：PCT/US2018/000243
申请日：2018-08-16
IPC分类号： C07D473/18 , A61K31/522 , A61P37/04
摘要： Compounds having a structure according to formula (I). where R 1 and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
-
公开(公告)号：WO2022241171A1
公开(公告)日：2022-11-17
申请号：PCT/US2022/029102
申请日：2022-05-13
发明人： SPERGEL, Steven, H. , MOSLIN, Ryan, M. , MERTZMAN, Michael, Edward , TINO, Joseph, A. , POSY, Shoshana, L. , LAKKARAJU, Sirish Kaushik , XIAO, Zili , KEMPSON, James
IPC分类号： C07D401/14 , C07D403/12 , A61P29/00 , A61P37/00 , A61K31/501
摘要： There are disclosed compounds of the following formula (I) or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
-
公开(公告)号：WO2022040260A1
公开(公告)日：2022-02-24
申请号：PCT/US2021/046421
申请日：2021-08-18
IPC分类号： C07D401/14 , C07D451/02 , C07D451/04 , C07D403/10 , C07D405/12 , C07D471/04 , C07D487/10 , C07D487/04 , A61K31/4184 , A61P1/16 , A61P1/18 , A61P13/12 , A61P11/00
摘要： The present invention relates to lH-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis, renal fibrosis, biliary fibrosis or pancreatic fibrosis, nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis (PSC) or primary biliary cirrhosis (PBC), or idiopathic pulmonary fibrosis (IPF).
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.013 秒)
